Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Cancer. 2019 Jul 10;125(21):3790–3800. doi: 10.1002/cncr.32340

Figure 3: — Adverse events possibly related to treatment in the bevacizumab/dasatinib arm (A) and bevacizumab arm (B). AEs are included when 2 or more patients have grade 3 or 4 AEs, or 10 or more patients have grade 1 or 2 AEs which are deemed to be at least possibly related to treatment.

Figure 3: — Adverse events possibly related to treatment in the bevacizumab/dasatinib arm (A) and bevacizumab arm (B). AEs are included when 2 or more patients have grade 3 or 4 AEs, or 10 or more patients have grade 1 or 2 AEs which are deemed to be at least possibly related to treatment.